医学文献 >>
  • 检索发现
  • 增强检索
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
默认
×
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

Saponin Ⅰ from Shuitianqi(Rhizoma Schizocapasae Plantagineae)inhibits metastasis by negatively regulating the transforming growth factor-β1/Smad7 network and epithelial-mesenchymal transition in the intrahepatic metastasis Bagg's Albino/c mouse model

摘要OBJECTIVE:To examine the influence of Saponin Ⅰ from Shuiti anqi(Rhizoma Schizocapasae Plantagineae)(SSPH Ⅰ)on hepatocellular carcinoma(HCC)metastasis,and to elucidate the underlying mechanism.METHODS:The intrahepatic metastasis Bagg's Albino/c(BALB/c)mouse model was established with human hepatocellular carcinomas(HepG2)cells,then treated with normal saline(once per day),cisplatin(2 mg/kg,once every 2 d),and SSPH Ⅰ(25,50,and 75 mg/kg,once per day).Then,we assessed alterations in the hepatic pathology and target protein expressions in the intrahepatic metastasis BALB/c mouse model using a series of molecular biology techniques.RESULTS:Based on our analysis,SSPH Ⅰ significantly alleviated hepatocyte necrosis and tumor cells infiltration.Moreover,SSPH Ⅰ suppressed extracellular matrix(ECM)degradation and angiogenesis via a decrease in matrix etalloproteinase-2(MMP-2),MMP-9,CD31,CD34,and vascular endothelial growth factor(VEGF)levels.Furthermore,SSPH Ⅰ repressed invasion and meta-stasis by suppressing the transforming growth factor-β 1(TGF-β 1)/Smad7 axis and epithelial-mesenchymal transition(EMT),as evidenced by the scarce TGF-β1,N-cadherin,and Vimentin expressions,and elevated Smad7 and E-cadherin expressions.CONCLUSION:The SSPH Ⅰ-mediated negative regulation of the TGF-β 1/Smad7 axis and EMT are critical for the inhibition of HCC invasion and metastasis.

更多
广告
作者 LYU Meixian [1] ZHOU Huan [2] ZHI Limin [3] ZHOU Jinling [4] GAN Rizhi [5] QIN Yanping [6] HE Nengting [7] ZUO Qiqi [8] LI Hao [1] DONG Min [1] LIANG Gang [1] 学术成果认领
作者单位 Pharmaceutical College,Guangxi Medical University,Nanning 530022,China [1] Department of Pharmacy,Affiliated Tumor Hospital of Guangxi Medical University,Nanning 530022,China [2] Drug clinical trial Facility office,the People's Hospital of Guangxi Zhuang Autonomous Region,Nanning 530022,China [3] College of Pharmacy,Guangxi University of Chinese Medicine,Nanning 530022,China [4] Department of Pharmacy,the Second Affiliated Hospital of Guangxi Medical University,Nanning 530005,China [5] Department of Pharmacy,People's Hospital of Guangxi Hezhou,Hezhou 542899,China [6] Department of Pharmacy,Guangzhou Women and Children's Medical Center Liuzhou Hospital,Liuzhou 545000,China [7] Department of Pharmacy,First Affiliated Hospital of Gannan Medical University,Gannan 341000,China [8]
栏目名称
DOI 10.19852/j.cnki.jtcm.2024.04.006
发布时间 2024-11-11(万方平台首次上网日期,不代表论文的发表时间)
提交
  • 浏览2
  • 下载0
中医杂志(英文版)

中医杂志(英文版)

2024年44卷4期

642-651页

SCIMEDLINECSCDCA

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

法律状态公告日 法律状态 法律状态信息

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new医文AI 翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷